Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with Chemotherapy in Advanced Biliary Tract Cancer
NCT03046862Phase 2Active, not recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2017
- Primary completion
- May 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in biliary tract cancer (BTC), sponsored by Seoul National University Hospital. Primary endpoint: Response Rate at 6 weeks. Started Feb 2017; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03046862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03046862.